Breaking News
January 17, 2018 - Raw Meat Not the Safest Choice for Your Dog or for You
January 17, 2018 - High-Dose Aspirin Preferred for Kawasaki’s
January 17, 2018 - Study suggests risk management approach to combat EMS fatigue
January 17, 2018 - A new therapy against obesity
January 17, 2018 - Doctors warn against holding your nose and closing your mouth to contain a sneeze
January 17, 2018 - Measles outbreak alarms public health officials
January 17, 2018 - FDA Slaps Class Warning on Gadolinium Contrast Agents
January 17, 2018 - Distinct human mutations can alter the effect of medicine
January 17, 2018 - ASIT biotech’s new article presents clinical results of gp
January 17, 2018 - Alternative tobacco use by adolescents associated with greater odds of future cigarette smoking
January 17, 2018 - A High-Salt Diet Produces Dementia In Mice
January 17, 2018 - Scientists provide insights into crucial interaction for DNA repair
January 17, 2018 - Sanofi and Regeneron Announce Positive Topline Pivotal Results for PD-1 Antibody Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma
January 17, 2018 - Morning Break: Pfizer Kills AD/PD Pipeline; Trump Affirms His Mental Health; Humira Pricing Strategy
January 17, 2018 - Researchers see gene influencing performance of sleep-deprived people
January 17, 2018 - Fast food triggers the immune system making it hyperactive
January 17, 2018 - Scientists find increased risk of HIV outbreaks in Ukraine due to war-related migration
January 17, 2018 - New universal flu vaccine moves to clinical trial phase and could be a reality soon
January 17, 2018 - Cocaine de-addiction breakthrough shows promise
January 17, 2018 - FDA Accepts New Drug Application for Seysara (sarecycline) for the Treatment of Moderate to Severe Acne
January 17, 2018 - Robotic Telestenting; BP Cuff Smartwatch; Medicare Bundled Care
January 17, 2018 - New cellular approach found to control progression of chronic kidney disease
January 17, 2018 - Lamprey genes provide clues to repair spinal cord damage, finds study
January 17, 2018 - Tissue-based soft robot could lead to advances in bio-inspired robotics
January 17, 2018 - Mostly the healthy and wealthy Americans use mobile phone apps to track sleep habits
January 17, 2018 - FDA Alert: Varubi (rolapitant) Injectable Emulsion: Health Care Provider Letter
January 16, 2018 - NeuroBreak: Rough Days for Neuroscience Research; Another Migraine Drug Advances
January 16, 2018 - The ‘greatest pandemic in history’ was 100 years ago – but many of us still get the basic facts wrong
January 16, 2018 - Serena Williams Shares Childbirth Ordeal
January 16, 2018 - The Artificial Brain as Doctor
January 16, 2018 - Type 2 diabetes has hepatic origins
January 16, 2018 - Expert discusses how to identify, support individuals with drug or alcohol addiction in workplace
January 16, 2018 - Starting menstruation early increases risk of cardiovascular disease and stroke in later life
January 16, 2018 - CapsoVision receives CE Mark approval for use of CapsoCam Plus System in pediatric patients
January 16, 2018 - Researchers develop new dynamic statistical model to follow gene expressions over time
January 16, 2018 - Alzheimer’s ‘looks like me, it looks like you’
January 16, 2018 - By the Numbers: Physicians’ Economic Impact
January 16, 2018 - Sound Health | NIH News in Health
January 16, 2018 - Modifying baby formula doesn’t prevent type 1 diabetes in children
January 16, 2018 - Energy drinks dangerous for kids
January 16, 2018 - When you need a breast screening, should you get a 3-D mammogram?
January 16, 2018 - Johns Hopkins gets approval to perform HIV positive to HIV positive living donor kidney transplants
January 16, 2018 - The Salk Institute and Indivumed collaborate for cutting-edge cancer research
January 16, 2018 - Study reveals negative long-term effects of heavy cannabis use on brain function and behavior
January 16, 2018 - Many gym-goers injure themselves by pushing harder to be better than friends
January 16, 2018 - Risankizumab Meets All Primary Endpoints Reporting Positive Results in Fourth Pivotal Phase 3 Psoriasis Study
January 16, 2018 - Federal Junk Food Tax Feasible, Study Says
January 16, 2018 - Do girls have stronger teeth than boys?
January 16, 2018 - New high-sensitivity blood tests could aid faster diagnosis and treatment for heart attack
January 16, 2018 - How fatal mitochondrial diseases may strike offspring of families with no history of the conditions
January 16, 2018 - TherapeuticsMD Announces FDA Acceptance of New Drug Application and Prescription Drug User Fee Act (PDUFA) Date for TX-004HR
January 16, 2018 - Morning Break: Food Pharmacies; Obamacare Sign-ups Dip; Top Pot Studies
January 16, 2018 - Blood pressure declines 14 to 18 years before death
January 16, 2018 - ViLim Ball technology helps reduce uncontrollable shaking hands
January 16, 2018 - Researchers use immune-mimicking biomaterial scaffolds to fast track T cell therapies
January 16, 2018 - In Wisconsin, hopes rise for production of a lifesaving radioactive isotope
January 16, 2018 - Researchers develop software to better predict risk of leakage around aortic stents
January 16, 2018 - Bile acids could directly burn away lipids in the fat depots
January 16, 2018 - Cycling does not negatively impact sexual and urinary health finds study
January 16, 2018 - Severe peer victimization in childhood may contribute to mental health issues in adolescence
January 16, 2018 - Exelixis Announces U.S. FDA Approval of Cabometyx (cabozantinib) Tablets for Previously Untreated Advanced Renal Cell Carcinoma
January 16, 2018 - Just How Often Do Patients Turn Post-Surgical Opioids Into a Habit?
January 16, 2018 - Opioid addiction – Genetics Home Reference
January 16, 2018 - Incomplete revascularization in PCI linked to higher mortality
January 16, 2018 - Machine learning algorithm uses brain scans to predict language ability in deaf children
January 16, 2018 - Penn scientists identify new therapeutic target for treatment of melanoma
January 16, 2018 - The London Clinic exhibits innovative technology to treat Parkinson’s disease at Arab Health
January 16, 2018 - Early influenza testing is critical to prevent serious complications
January 16, 2018 - Study Gets to the Core of Back Pain in Runners
January 16, 2018 - Year in Review: Ophthalmology | Medpage Today
January 16, 2018 - ClinicalTrials.gov: Marijuana Use
January 16, 2018 - Researchers create novel compound targeting melanoma cells
January 16, 2018 - FDA grants approval for first drug to treat inherited breast cancer
January 16, 2018 - Researchers develop remote-controlled mechanogenetics system to target and kill cancer cells
January 16, 2018 - Fresh, Frozen Embryos Equal in IVF
January 16, 2018 - Research shows biological clocks could improve brain cancer treatment
January 16, 2018 - Dire view from within accident and emergency wards of England and Wales
January 16, 2018 - Study reveals how devastating mitochondrial diseases strike families without any previous history
January 16, 2018 - Experts look for ways to standardize treatments for pediatric rheumatic diseases
January 16, 2018 - Teens who watch TV shows with ads likely to eat more junk food
FDA Updates the Label of Tasigna to Reflect that Certain Patients with a Type of Leukemia May be Eligible to Stop Treatment After Sustained Response

FDA Updates the Label of Tasigna to Reflect that Certain Patients with a Type of Leukemia May be Eligible to Stop Treatment After Sustained Response

image_pdfDownload PDFimage_print

December 22, 2017 — The U.S. Food and Drug Administration today updated the product label for the cancer drug Tasigna (nilotinib) to include information for providers about how to discontinue the drug in certain patients. Tasigna, first approved by the FDA in 2007, is indicated for the treatment of patients with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML). With today’s updated dosing recommendations, patients with early (chronic) phase CML who have been taking Tasigna for three years or more, and whose leukemia has responded to treatment according to specific criteria as detected by a test that has received FDA marketing authorization, may be eligible to stop taking Tasigna.

“Patients diagnosed with CML generally face a lifetime of treatment to keep their leukemia from growing or recurring,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Today’s approval shows that some patients may be able to stop treatment with Tasigna altogether if they are showing a strong response to therapy. While we welcome this progress in patient care, it’s important to note that any discontinuation of treatment still means patients must be regularly monitored for disease recurrence.”

CML is a cancer of the bone marrow and causes the body to make too many white blood cells. Almost all patients with CML have an abnormality known as the Philadelphia chromosome, which produces a protein called BCR-ABL. The National Cancer Institute at the National Institutes of Health estimates approximately 8,950 patients will be diagnosed with CML this year, and 1,080 will die of the disease.

Tasigna is a kinase inhibitor that works in CML by blocking a protein called BCR-ABL, which promotes abnormal cell growth. Today’s action adds information to the product label for patients and health care providers regarding the conditions under which patients may be eligible to discontinue treatment and notes that if treatment is stopped patients must be regularly monitored for disease recurrence.

The information about discontinuing Tasigna was based on two single-arm trials of patients with Ph+ chronic phase CML. The trials measured how long patients were able to stop taking Tasigna without the leukemia returning (treatment-free remission, or TFR). In both trials, patients had to meet rigorous criteria showing how their cancer had responded to treatment before stopping Tasigna. In the first trial, among the 190 newly diagnosed patients with CML who stopped Tasigna after taking it for three or more years and meeting other specified criteria, 51.6 percent were still in the TFR phase after approximately one year (48 weeks) and 48.9 percent were still in the TFR phase after approximately two years (96 weeks). In the second trial, among the 126 patients who had stopped Tasigna after taking it for three or more years after switching from the cancer drug imatinib, 57.9 percent were still in the TFR phase after approximately one year (48 weeks) and 53.2 percent were still in the TFR phase after approximately two years (96 weeks).

An important part of both trials was regular and frequent monitoring of specific genetic (RNA) information that specifies the BCR-ABL protein level in the blood with a diagnostic test that has received FDA marketing authorization. Monitoring with a test able to detect reductions of specific RNA information with high accuracy and precision is critical to the safe discontinuation of Tasigna, as this monitoring provides the first signs of relapse.

Common side effects in patients who discontinued Tasigna include musculoskeletal symptoms such as body aches, bone pain and pain in extremities. Some patients experienced prolonged musculoskeletal symptoms.

Common side effects of taking Tasigna include nausea, rash, headache, fatigue, itching (pruritus), vomiting, diarrhea, cough, constipation, joint pain (arthralgia), upper respiratory inflammation (nasopharyngitis), fever (pyrexia), night sweats, low levels of low blood platelets (thrombocytopenia) and low levels of certain blood cells (myelosuppression or thrombocytopenia, neutropenia and anemia).

Severe side effects of taking Tasigna include myelosuppression, blockages in the heart or arteries (cardiac and arterial vascular occlusive events), inflammation of the pancreas and high levels of enzymes in the blood (pancreatitis and elevated serum lipase), severe liver damage (hepatotoxicity), abnormal levels of electrolytes in the blood, metabolic abnormalities (tumor lysis syndrome), severe bleeding (hemorrhage), drug interactions with CYP3A4 inhibitors, total surgical removal of the stomach (gastrectomy) and fluid retention. Women who are pregnant or breastfeeding should not take Tasigna because it may cause harm to a developing fetus or newborn baby.

Severe side effects typically associated with Tasigna administration occurred less frequently in patients who discontinued Tasigna. However, the long-term outcomes of patients discontinuing versus continuing treatment are unknown at this time.

The labeling for Tasigna contains a boxed warning to alert health care professionals and patients about the risk of abnormal heart rhythm (QT prolongation) and sudden death. Tasigna should not be taken by patients with low levels of potassium in the blood (hypokalemia), low levels of magnesium in the blood (hypomagnesemia), or QT prolongation. Sudden deaths have been reported in patients taking Tasigna. The boxed warning also states Tasigna should not be given with drugs known to prolong the QT interval or with strong CYP3A4 inhibitors. Patients should not eat two hours prior to or one hour after taking Tasigna.

The update to the Tasigna labeling information was granted Priority Review, under which the FDA’s goal is to take action on an application within six months where the agency determines that the drug, if approved, would significantly improve the safety or effectiveness of treating, diagnosing or preventing a serious condition. Tasigna also received Orphan Drug designation, which provides incentives to assist and encourage the development of drugs for rare diseases.

The FDA granted the approval of the Tasigna label changes to Novartis Pharmaceuticals Corporation.

Source: FDA

Posted: December 2017

Related Articles:

Tasigna (nilotinib) FDA Approval History

Tagged with:

About author

Related Articles